Clinical Trial: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469488) titled 'A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens' on March 03.

Brief Summary: This study aims to explore the clinical outcomes of Comprehensive Enhanced Preventive Management (CEPM) combined with an amivantamab-containing treatment regimen in Chinese patients with EGFR-mutated advanced NSCLC.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: NSCLC (Advanced Non-small Cell Lung Cancer) VTE (Venous Thromboembolism) Rash Due to Epidermal Growth Factor Receptor Inhibitors Infusion Reaction...